1.Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.
Charlotte VAYSSE ; Cyril TOUBOUL ; Thomas FILLERON ; Eliane MERY ; Eva JOUVE ; Pierre LEGUEVAQUE ; Philippe MORICE ; Eric LEBLANC ; Denis QUERLEU
Journal of Gynecologic Oncology 2011;22(1):9-17
OBJECTIVE: Early stage primary carcinoma of the fallopian tube (PCFT) is an uncommon condition when strict criteria are applied. The aim of this study was to compare the outcome stage IA-IB PCFT to a matched group of ovarian cancer (OC). METHODS: Between 1990 and 2008, 32 patients with stage IA-IB of PCFT were recorded in the database of three French Institutions. A control group of patients with OC was constituted. RESULTS: Eleven eligible PCFT cases and 29 OC controls fulfilled the stringent inclusion criteria. Median follow-up was 70.2 months. Five-year overall survival was 83.3% (95% confidence interval [CI], 27.3 to 97.5) for PCFT and 88.0% (95% CI, 66.9 to 96.0) for OC (p=0.93). In the subgroup of patients with grade 2-3, the outcome was similar in PCFT compared to OC patients (p=0.75). Five-year relapse-free survival was respectively 62.5% (95% CI, 22.9 to 86.1) and 85.0% (95% CI, 64.6 to 94.2) in the PCFT and OC groups (p=0.07). In the subgroup of patients (grade 2-3), there was no difference between PCFT and OC (p=0.65). CONCLUSION: The findings did not reveal any difference in prognosis between early stage of PCFT and OC when grade is taken into account. Management of PCFT should mirror that of ovarian carcinoma.
Adenocarcinoma
;
Case-Control Studies
;
Fallopian Tubes
;
Female
;
Follow-Up Studies
;
Humans
;
Ovarian Neoplasms
;
Ovary
;
Prognosis
;
Research Design
2.Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
Martina Aida ANGELES ; Bastien CABARROU ; Antonio GIL-MORENO ; Asunción PÉREZ-BENAVENTE ; Emanuela SPAGNOLO ; Agnieszka RYCHLIK ; Carlos MARTÍNEZ-GÓMEZ ; Frédéric GUYON ; Ignacio ZAPARDIEL ; Denis QUERLEU ; Claire ILLAC ; Federico MIGLIORELLI ; Sarah BÉTRIAN ; Gwénaël FERRON ; Alicia HERNÁNDEZ ; Alejandra MARTINEZ
Journal of Gynecologic Oncology 2021;32(6):e78-
Objective:
We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer (OC) with minimal (CC-1) or no residual disease (CC-0).
Methods:
This retrospective study included patients with International Federation of Gynaecology and Obstetrics IIIC–IV stage OC who underwent debulking surgery at 4 high-volume institutions between January 2008 and December 2015. We assessed the overall survival (OS) of primary debulking surgery (PDS group), early interval debulking surgery after 3–4 cycles of NACT (early IDS group) and delayed debulking surgery after 6 cycles (DDS group) with CC-0 or CC-1 according to peritoneal cancer index (PCI) and Aletti score.
Results:
Five hundred forty-nine women were included: 175 (31.9%) had PDS, 224 (40.8%) early IDS and 150 (27.3%) DDS. Regardless of Aletti score, median OS after PDS was significantly higher than after early IDS or DDS, but the survival difference was higher in women with an Aletti score <8. Among patients with PCI ≤10, median OS after PDS was significantly higher than after early IDS or DDS. In women with PCI >10, there were no differences between PDS and early IDS, but DDS was associated with decreased OS.
Conclusion
The benefit of complete PDS compared with NACT was maximal in patients with a low complexity score. In patients with low tumor burden, there was a survival benefit of PDS over early IDS or DDS. In women with high tumor load, DDS impaired the oncological outcome.